Navigation Links
NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
Date:2/29/2008

BEDMINSTER, N.J., Feb. 29 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., executive vice president, chief operating officer, and chief executive officer-elect is scheduled to present at the Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami on Wednesday, March 19, 2008 at 3:15 p.m. ET. The presentation will be available as a live webcast with a replay available approximately 24 hours after the presentation has concluded. Interested parties may access the webcast from the NPS website, http://www.npsp.com.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing high value specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and parathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. NPS has also completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84 [rDNA origin] injection). NPS complements its internal programs with strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and Nycomed. Additional information is available at http://www.npsp.com.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
2. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
3. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
4. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
5. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Regen BioPharma Inc. (OTCQB: ... of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with early ... NR2F6 in patient,s cervical cancer tissue as well as in ... "This is an interesting study and the first that I ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... website, http://www.autoreactors.com and online shopping cart. The new website has been ... functionality. These essential digital components allow customers to access detailed product information, read ...
(Date:12/6/2016)... , Dec. 6, 2016 The American Botanical ... adoption of arnica ( Arnica montana ) through ... ABC,s HerbMedPro database, a comprehensive, interactive ... and clinical research data on the uses and ... Naturopathica, a wellness company with healing ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Osteoarthritis Research Society International ... Administration (FDA) to consider OA as a serious disease. As an organization of ... population of OA patients, many of whom may experience progressive disability and decreased ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):